Jeffrey William, MD
Nephrology · Boston, MANPI 1033439716
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $127 of the $153 with a category attached, or 83.2%. Novo Nordisk accounts for 83.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for nephrology clinicians in MA, where the typical reported total is $287.
Across 9 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$127
- Travere Therapeutics, Inc.$26
Across 3 payments — averaging $19,927 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$60K
What the payments were for
- Food & beverage$12783%
- Education$2617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $127 |
| Travere Therapeutics, Inc. | 8 | $26 |
How this compares
$153 in reported general payments places this provider in the 40th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 76 | $92,475 |
| JardianceEmpagliflozin | 73 | $80,723 |
| Sevelamer Carbonate | 69 | $8,591 |
| ProcritEpoetin Alfa | 12 | $7,633 |
| Calcitriol | 217 | $3,815 |
| RetacritEpoetin Alfa-Epbx | 15 | $3,494 |
| Losartan Potassium | 131 | $1,823 |
| Potassium Citrate ErPotassium Citrate | 34 | $1,818 |
| Candesartan Cilexetil | 17 | $1,637 |
| Torsemide | 57 | $1,613 |
| Midodrine Hcl | 28 | $1,311 |
| Valsartan | 19 | $1,263 |
| Irbesartan | 24 | $1,193 |
| Amlodipine Besylate | 101 | $940 |
| Lisinopril | 98 | $690 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Boston
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Leslie FangBoston$388K
- Jean FrancisBoston$244K
- Joseph BonventreBoston$175K
- Andrew AllegrettiBoston$139K
- Ravi ThadhaniBoston$115K
- Meghan SiseBoston$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.